Jaguar Health FY26 Q2 net loss narrows 80.7% to USD 4.08 million; revenue rises 314% to USD 21.5 million

Reuters2026/08/19 17:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jaguar Health posted a net loss of USD 4.08 million for the six months ended June 30, 2026, narrowing 80.7%.
Revenue climbed to USD 21.5 million, up 314%, driven by USD 19.09 million of license revenue.
Product revenue fell to USD 2.39 million, down 53.3%, reflecting lower Mytesi volume following the January 2026 Woodward licensing deal.
Operating income turned positive at USD 2.59 million, versus an operating loss in the prior-year period.
Cash was USD 3.8 million at June 30, 2026; management said the January 2026 upfront fees did not remove going-concern doubt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-356570), on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Jaguar Health FY26 Q2 net loss narrows 80.7% to USD 4.08 million; revenue rises 314% to USD 21.5 million

You may also like

Crypto prices